News
Square Enix has revealed new info about the next update coming to Final Fantasy XIV, as they unveiled Patch 7.3: The Promise ...
2d
FullCleared on MSNFinal Fantasy XIV Patch 7.3 Aims for August ReleaseThe Promise of Tomorrow. Set to launch in early August 2025, Patch 7.3 will include new main scenario quests, the next ...
Final Fantasy XIV Patch 7.3 will launch in August, Square Enix has confirmed, and it'll bring new dungeons, a new 24-player ...
2d
Game Rant on MSNFinal Fantasy 14 Shares First Patch 7.3 DetailsFinal Fantasy 14 pulls back the curtain on Patch 7.3, The Promise of Tomorrow, which will also be the climax of Dawntrail's ...
Toyota’s been rather sluggish on the transition to EVs, instead taking a slow approach by shifting most of its lineup from combustion engines to hybrid powertrains. Don’t count Toyota out of ...
The airline in September predicted that new fees would lead to $1.5 billion a year in revenue. Last year, JetBlue brought Uber-style surge pricing to bag-check fees, making it more costly to check ...
The Final Fantasy 14 7.25 patch notes are here, and they detail the game's Occult Crescent exploration zone, new Hildibrand Adventures, Mamool Ja allied society quests, and job buffs. So if you've ...
Not anymore. In this new guide, Tines breaks down how modern IT orgs are leveling up with automation. Patch faster, reduce overhead, and focus on strategic work -- no complex scripts required.
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the ...
The Denver Nuggets enter Sunday’s Game 7 against the Oklahoma City Thunder looking to steal another victory on the road and advance to the Western Conference Finals. Denver was able to extend ...
Consumer sentiment and inflation expectations have worsened this year even as so-called hard data reveal stable price pressures and robust hiring. U.S. payrolls rose 177,000 last month, with ...
However, he believes Pfizer will be an "EPS [earnings per share] growth story" thanks to its cost reductions, business development, and new product launches. Again, though, Bourla's optimism is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results